Inhalon
Thomas is an infectious disease physician/scientist and served on the faculty of JHU School of Medicine for over 10 years. As Chief Medical Officer at Mapp, he oversaw the clinical development of ZMapp, a cocktail of 3 mAbs for treatment of Ebola, as well as the preclinical development and clinical study of MB66, a vaginal film loaded with two anti-viral mAbs. He was the Principle Investigator (PI) of over $144M in BARDA funding for the development of ZMapp and co-PI of a $13.3M NIAID-sponsored multicenter microbicide program that funded the MB66 work. As such, he has experience in both clinical development and the industrialization of biologics as well as drug-device combinations for infectious diseases.
This person is not in any offices
Inhalon
Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.